SODIUM VALPROATE/VALPROIC ACID

InPharma ◽  
1978 ◽  
Vol 163 (1) ◽  
pp. 19-19
Keyword(s):  
Valproic Acid ◽  
Sodium Valproate

scholarly journals Analytical Method Development for Sodium Valproate through Chemical Derivatization

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Murad Abualhasan ◽  
Nihaya Wasif Odeh ◽  
Ghadeer Naser Younis ◽  
Oyoun Fadel Zeidan
Keyword(s):  
Valproic Acid ◽  
Sodium Valproate ◽  
Analytical Method ◽  
Method Development ◽  
Analytical Procedure ◽  
Phenyl Group ◽  
Chemical Derivatization ◽  
Reverse Phase Hplc ◽  
Reverse Phase ◽  
Low Concentrations

Background. Sodium valproate has anticonvulsant activity and is structurally different to conventional antiepileptic drugs. The problem with valproic acid is the lack of a chromophore, which means that gas chromatography is the sole assay methodology. The introduction of benzoyl and phenyl groups to the molecule is a useful derivatisation, which enables the creation of detectable chromophores for HPLC analysis for pharmaceutical dosages as well as biological systems. Methodology. Sodium valproate was derivatised by the addition of a chromophore to its structure by introducing a methyl benzoyl or a phenyl group. Trichlorophenol and 2-hydroxyacetophenone were used to introduce phenyl and benzoyl groups to valproic acid, respectively. The reaction used was estrification reaction using coupling agents. An analytical method was then developed and validated using reverse-phase HPLC. The method was validated for parameters like linearity, range, accuracy precision, and robustness. Results. The developed method was easy and feasible and can be applied to both routine analysis and bioanalysis. The method was very sensitive and could quantify valproic acid at a very low concentration of 0.75 × 10−5 mg/ml. The developed method was found to be linear (R2 = 0.997), accurate, precise, and robust. Conclusion. The proposed chemical derivatisation and the developed analytical method are novel. The developed analytical procedure is the first of its kind; it is easy and feasible and can be used to quantify and detect sodium valproate at very low concentrations compared to other available methods in the literature.

scholarly journals Analytical method validation for related substances in sodium valproate oral solution by gas chromatography

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
R. Chandrasekar ◽  
B. Sivagami ◽  
M. Eswarisai ◽  
P. Nandini ◽  
Y. Pallavi ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Gas Chromatography ◽  
Sodium Valproate ◽  
Oral Solution ◽  
Fused Silica ◽  
Valeric Acid ◽  
Solution Stability ◽  
Analytical Method Validation ◽  
Related Substances

Abstract Background Sodium Valproate is the sodium salt of valproic acid (VPA). Valproic acid is mainly used for the treatment of epilepsy. The specific aim of the study is to develop and validate an optimized method for the determination of six related substances such as N,N-dimethyl valpronamide, valeric acid, 2-methyl valeric acid, 2-ethyl valeric acid, 2-isopropyl valeric acid and 2-n-butyl valeric acid in Sodium Valproate Oral Solution by Gas Chromatography. Chromatographic separations of these six related substances were achieved on DB-FFAP fused silica capillary column (30 m × 0.53 mm) bonded with a 0.5-µm layer of macrogol 20,000 2-nitroterephthalate materials used as stationary phase. The six related impurities were extracted using heptane and monitored by Gas Chromatography coupled with flame ionization detector. The performance of the developed method was assessed by evaluating system suitability, method precision, specificity, linearity and range, ruggedness, accuracy, robustness. Results The correlation coefficient was within the acceptance criteria in the range of 0.9998. The evaluated concentrations for Sodium Valproate were in the ranges of 5.05–25.27 ppm. The average recovery values were in the range of 92.4–100.4%. Solution Stability experiments were performed to evaluate the degradation behavior of SVS. Conclusion A novel, precise and sensitive GC method was developed, validated and optimized for the determination of six related substances in sodium Valproate oral solution. The results obtained from the validation experiments demonstrated that the method is accurate, precise, linear, specific, sensitive and robust. Hence, the proposed method can be an alternative method, for the determination of related substances in sodium valproate oral solution drug substance.

scholarly journals Influence of sodium valproate treatment on body mass and insulin resistance parameters in children with epilepsy

2020 ◽  
pp. 84-84
Author(s):  
Aleksandar Dimitrijevic ◽  
Radan Stojanovic ◽  
Dragana Bogicevic ◽  
Vesna Mitic ◽  
Dimitrije Nikolic
Keyword(s):  
Valproic Acid ◽  
Weight Gain ◽  
Sodium Valproate ◽  
Glucose Homeostasis ◽  
Acid Treatment ◽  
Statistical Significance ◽  
Insulin Level ◽  
Serum Glucose ◽  
Drug Discontinuation ◽  
Healthy Children

Introduction/Objective. One of the main side-effects in patients undergoing valproic acid treatment is weight gain. Weight gain might be the reason for drug discontinuation, especially in adolescent girls, and it has to be considered also before introducing the drug. The main goal of our study is to investigate a possible influence of antiepileptic therapy with sodium valproate on weight and glucose homeostasis in pediatric patients with epilepsy. Methods. The investigation included a total of 49 healthy children with recently diagnosed epilepsy. We measured height, weight and serum 12-hour overnight fasting glucose and insulin level before initiation and after 6- and 12-month valproic acid treatment period. The BMI and HOMA indexes were calculated for each patient and correlated after the initiation of therapy and after 6 and 12 months of therapy. Results. We found that children significantly gained weight with statistical significance (p<0.01) even after 6 months of therapy with a significant glucose metabolism change and statistical difference in average serum glucose and insulin levels (p<0.05). Conclusion. Our results show that a 12-month treatment with valproic acid in children with epilepsy has a great impact on weight gain and glucose homeostasis and metabolism. We strongly recommend that all children with recently diagnosed epilepsy at the initiation of valproate therapy should be closely monitored on a 6-month basis. Consultation of nutritionist is advised especially in children with preexisting problem with body weight.

Sign in / Sign up

Export Citation Format

Share Document